PE20231385A1 - Composiciones de vacunas multivalentes y usos de las mismas - Google Patents

Composiciones de vacunas multivalentes y usos de las mismas

Info

Publication number
PE20231385A1
PE20231385A1 PE2023001175A PE2023001175A PE20231385A1 PE 20231385 A1 PE20231385 A1 PE 20231385A1 PE 2023001175 A PE2023001175 A PE 2023001175A PE 2023001175 A PE2023001175 A PE 2023001175A PE 20231385 A1 PE20231385 A1 PE 20231385A1
Authority
PE
Peru
Prior art keywords
antigen
infections
coli
expec
concentration
Prior art date
Application number
PE2023001175A
Other languages
English (en)
Inventor
Kellen Cristhina Fae
Michal Sarnecki
Jeroen Geurtsen
Darren Robert Abbanat
Bart Gustaaf M Spiessens
Frank Germaine F Struyf
Jan Theunis Poolman
Original Assignee
Janssen Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceuticals Inc filed Critical Janssen Pharmaceuticals Inc
Publication of PE20231385A1 publication Critical patent/PE20231385A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0258—Escherichia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/739—Lipopolysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55583—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicinal Preparation (AREA)

Abstract

Esta referida a una composicion que comprende polisacaridos de antigeno O1, O2, O4, O15, O16, O18, O25, O75 y O6 de E. coli, en donde cada uno de los polisacaridos de antigeno esta unido independientemente de manera covalente a una proteina portadora, y en donde la concentracion de cada polisacarido de antigeno O75 y O25 aumenta independientemente con respecto a la concentracion de cada uno de los polisacaridos de antigeno O1, O2, O4, O15, O16, O18 y O6. La vacunacion con una composicion que contiene conjugados del antigeno O75 de E. coli y conjugados de uno o mas antigenos O adicionales de E. coli a una dosis y proporcion adecuadas proporciona una respuesta inmunitaria mejorada contra el serotipo O75 de ExPEC y los uno o mas serotipos O adicionales de ExPEC. Las cepas ExPEC son la causa mas comun de infeccion de las vias urinarias (IVU). Tambien contribuyen a las infecciones del sitio quirurgico y a la meningitis neonatal, asociadas con las infecciones abdominales y pelvicas y a la neumonia nosocomial, y ocasionalmente participan en otras infecciones extraintestinales como la osteomielitis, la celulitis y las infecciones de heridas.
PE2023001175A 2020-09-17 2021-09-17 Composiciones de vacunas multivalentes y usos de las mismas PE20231385A1 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202063079734P 2020-09-17 2020-09-17
EP21154782 2021-02-02
US202163191471P 2021-05-21 2021-05-21
PCT/IB2021/058485 WO2022058945A1 (en) 2020-09-17 2021-09-17 Multivalent vaccine compositions and uses thereof

Publications (1)

Publication Number Publication Date
PE20231385A1 true PE20231385A1 (es) 2023-09-12

Family

ID=77801756

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2023001175A PE20231385A1 (es) 2020-09-17 2021-09-17 Composiciones de vacunas multivalentes y usos de las mismas

Country Status (17)

Country Link
US (1) US20220088165A1 (es)
EP (1) EP4213870A1 (es)
JP (2) JP7481585B2 (es)
KR (1) KR20230043157A (es)
CN (1) CN115803087A (es)
AU (1) AU2021342797B2 (es)
BR (1) BR112023004819A2 (es)
CA (1) CA3190820A1 (es)
CL (1) CL2023000740A1 (es)
CO (1) CO2023002114A2 (es)
EC (1) ECSP23019295A (es)
IL (2) IL301248B2 (es)
MX (1) MX2023003169A (es)
PE (1) PE20231385A1 (es)
TW (1) TW202227128A (es)
UY (1) UY39428A (es)
WO (1) WO2022058945A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020240075A1 (en) 2019-03-18 2021-10-14 Janssen Pharmaceuticals, Inc. Methods of producing bioconjugates of e. coli o-antigen polysaccharides, compositions thereof, and methods of use thereof
EA202192390A1 (ru) 2019-03-18 2021-12-03 Янссен Фармасьютикалз, Инк. Биоконъюгаты полисахаридных о-антигенов e.coli, способы их получения и способы их применения
WO2024107729A2 (en) * 2022-11-15 2024-05-23 Janssen Pharmaceuticals, Inc. Multivalent vaccine compositions and uses thereof
WO2024146325A1 (zh) * 2023-01-06 2024-07-11 中国人民解放军军事科学院军事医学研究院 用于生产抗原多糖-载体蛋白生物偶联产物的工程菌及其应用
GB202302579D0 (en) * 2023-02-23 2023-04-12 Glaxosmithkline Biologicals Sa Immunogenic composition
WO2024186262A1 (en) * 2023-03-03 2024-09-12 Agency For Science, Technology And Research Use of o-antigens for treating bacterial infections

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
NZ249704A (en) 1992-02-11 1996-11-26 Jackson H M Found Military Med A two carrier immunogenic construct comprising a 70+ kd molecule conjugated to at least 1 t-dependent antigen, preparation, compositions containing the construct
ES2143716T3 (es) 1992-06-25 2000-05-16 Smithkline Beecham Biolog Composicion de vacuna que contiene adyuvantes.
ES2231770T3 (es) 1993-03-05 2005-05-16 Wyeth Holdings Corporation Nuevos plasmidos para la produccion de proteina crm y toxina difterica.
JP3828145B2 (ja) 1993-09-22 2006-10-04 ヘンリー エム．ジャクソン ファウンデイション フォー ザ アドバンスメント オブ ミリタリー メディスン 免疫原性構成物の製造のための新規シアン化試薬を使った可溶性炭水化物の活性化方法
NZ304715A (en) 1995-03-22 1999-07-29 Jackson H M Found Military Med Production of immunogenic constructs using organic cyanylating reagents to activate carbohydrates and then coupling the carbohydrate to a protein, peptide or hapten
US6299881B1 (en) 1997-03-24 2001-10-09 Henry M. Jackson Foundation For The Advancement Of Military Medicine Uronium salts for activating hydroxyls, carboxyls, and polysaccharides, and conjugate vaccines, immunogens, and other useful immunological reagents produced using uronium salts
TR199902437T2 (xx) 1997-04-01 2000-01-21 Corixa Corporation Monofosforil lipid A'ya ait sulu im�nolojik adjuvant terkipleri.
US6491919B2 (en) 1997-04-01 2002-12-10 Corixa Corporation Aqueous immunologic adjuvant compostions of monophosphoryl lipid A
CA2773698C (en) 1998-10-16 2015-05-19 Glaxosmithkline Biologicals S.A. Adjuvant systems comprising an immunostimulant adsorbed to a metallic salt particle and vaccines thereof
ATE398463T1 (de) 2000-04-13 2008-07-15 Corixa Corp Immunostimulierende zusammnensetzungen die aminoalkyl glucosaminidephosphat und qs-21 enthalten
US6676958B2 (en) 2001-06-19 2004-01-13 Advanced Bioadjuvants, Llc Adjuvant composition for mucosal and injection delivered vaccines
DK1481057T3 (da) 2002-03-07 2006-05-15 Eidgenoess Tech Hochschule System og fremgangsmåde til fremstilling af rekombinante glycosylerede proteiner i en prokaryot vært
ES2353814T3 (es) 2005-05-11 2011-03-07 Eth Zuerich Proteinas n-glicosiladas recombinantes de celulas procariotas.
TWI457133B (zh) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
CA2646891A1 (en) 2006-03-23 2007-09-27 Novartis Ag Immunopotentiating compounds
EP2357184B1 (en) 2006-03-23 2015-02-25 Novartis AG Imidazoquinoxaline compounds as immunomodulators
CA2711503A1 (en) 2008-01-08 2009-07-16 Biogenerix Ag Glycoconjugation of polypeptides using oligosaccharyltransferases
CN101983070B (zh) 2008-02-20 2016-03-30 格林考瓦因有限公司 由来源于原核细胞的重组n-糖基化蛋白制备生物共轭物
EP2437753B1 (en) 2009-06-05 2016-08-31 Infectious Disease Research Institute Synthetic glucopyranosyl lipid adjuvants and vaccine compositions containing them
WO2014027302A1 (en) 2012-08-16 2014-02-20 Pfizer Inc. Glycoconjugation processes and compositions
WO2014037585A1 (en) 2012-09-10 2014-03-13 Glycovaxyn Ag Bioconjugates comprising modified antigens and uses thereof
CA2887133C (en) 2012-10-12 2022-05-03 Glycovaxyn Ag Methods of host cell modification
EP4169929A1 (en) 2012-12-20 2023-04-26 Pfizer Inc. Immunogenic compositions comprising pn-serotype 12f
RS59500B1 (sr) 2013-05-18 2019-12-31 Aduro Biotech Inc Sastavi i metode za aktiviranje signaliziranja koje je zavisno od „stimulatora gena za interferon“
CN103495161B (zh) 2013-10-08 2019-06-18 江苏康泰生物医学技术有限公司 一种多元肺炎球菌荚膜多糖-蛋白质结合物的混合物及其制备方法
WO2015052344A1 (en) 2013-10-11 2015-04-16 Glycovaxyn Ag Methods of host cell modification
CA2932225C (en) 2013-12-04 2023-01-17 Glycovaxyn Ag Prevention of staphylococcus aureus infections by glycoprotein vaccines synthesized in escherichia coli
CA2940547C (en) * 2014-02-24 2021-01-05 Glycovaxyn Ag Novel polysaccharide and uses thereof
BR112016023688B1 (pt) 2014-04-17 2024-01-09 Glaxosmithkline Biologicals Sa Bioconjugado e uso de um bioconjugado
CN105695497B (zh) 2014-11-27 2019-09-24 中国人民解放军军事医学科学院生物工程研究所 一种细菌多糖修饰的重组融合蛋白的制备方法及其应用
MX2017008817A (es) 2014-12-30 2017-10-24 Glaxosmithkline Biologicals Sa Composiciones y metodos para la glicosilacion de proteinas.
TWI715617B (zh) * 2015-08-24 2021-01-11 比利時商葛蘭素史密斯克藍生物品公司 對抗腸道外病原性大腸桿菌之免疫保護之方法及組合物
GB201518668D0 (en) 2015-10-21 2015-12-02 Glaxosmithkline Biolog Sa Immunogenic Comosition
GB201610599D0 (en) 2016-06-17 2016-08-03 Glaxosmithkline Biologicals Sa Immunogenic Composition
AR109621A1 (es) * 2016-10-24 2018-12-26 Janssen Pharmaceuticals Inc Formulaciones de vacunas contra glucoconjugados de expec
US11260119B2 (en) * 2018-08-24 2022-03-01 Pfizer Inc. Escherichia coli compositions and methods thereof
EP3894431A2 (en) 2018-12-12 2021-10-20 GlaxoSmithKline Biologicals SA Modified carrier proteins for o-linked glycosylation
AU2020240075A1 (en) * 2019-03-18 2021-10-14 Janssen Pharmaceuticals, Inc. Methods of producing bioconjugates of e. coli o-antigen polysaccharides, compositions thereof, and methods of use thereof
EA202192390A1 (ru) * 2019-03-18 2021-12-03 Янссен Фармасьютикалз, Инк. Биоконъюгаты полисахаридных о-антигенов e.coli, способы их получения и способы их применения
WO2022208430A1 (en) * 2021-04-01 2022-10-06 Janssen Pharmaceuticals, Inc. Production of e. coli o18 bioconjugates

Also Published As

Publication number Publication date
WO2022058945A1 (en) 2022-03-24
KR20230043157A (ko) 2023-03-30
EP4213870A1 (en) 2023-07-26
US20220088165A1 (en) 2022-03-24
IL301248A (en) 2023-05-01
JP2024099716A (ja) 2024-07-25
CN115803087A (zh) 2023-03-14
CO2023002114A2 (es) 2023-03-07
ECSP23019295A (es) 2023-04-28
IL308201A (en) 2024-01-01
CL2023000740A1 (es) 2023-09-29
CA3190820A1 (en) 2022-03-24
AU2021342797A1 (en) 2023-02-16
UY39428A (es) 2022-03-31
BR112023004819A2 (pt) 2023-04-18
TW202227128A (zh) 2022-07-16
JP7481585B2 (ja) 2024-05-10
IL301248B2 (en) 2024-04-01
JP2023539943A (ja) 2023-09-20
MX2023003169A (es) 2023-03-27
IL301248B1 (en) 2023-12-01
AU2021342797B2 (en) 2024-02-08

Similar Documents

Publication Publication Date Title
PE20231385A1 (es) Composiciones de vacunas multivalentes y usos de las mismas
HRP20230947T1 (hr) Postupci i kompozicije za imunološku zaštitu od izvancrijevne patogene e. coli
Hatz et al. Safety and immunogenicity of a candidate bioconjugate vaccine against Shigella dysenteriae type 1 administered to healthy adults: A single blind, partially randomized Phase I study
EA202091382A1 (ru) Композиции, содержащие конъюгаты полисахарид streptococcus pneumoniae с белком, и способы их применения
Thomsen et al. Anti-Pseudomonas aeruginosa IgY antibodies augment bacterial clearance in a murine pneumonia model
CO2019007982A2 (es) Composiciones de neisseria meningitidis y métodos respectivos
ES2495744T3 (es) Glucanos con adyuvante
BR112012022669A2 (pt) composição imunogênica, método de tratamento ou prevenção de infecção ou doença, uso de um antígeno, kit, métodos para a fabricação de uma composição imunogênica e para melhorar uma vacina.
ES2828039T3 (es) Vacunas conjugadas de salmonela
Fingermann et al. OMV-based vaccine formulations against Shiga toxin producing Escherichia coli strains are both protective in mice and immunogenic in calves
ES2599908T3 (es) Glucanos beta-1,3-enlazados conjugados
Khim et al. Deimmunization of flagellin for repeated administration as a vaccine adjuvant
ES2537019T3 (es) Sacáridos Vi conjugados
Camacho et al. Towards a non-living vaccine against Shigella flexneri: from the inactivation procedure to protection studies
Delbaz et al. Biological and immunological evaluation of Neisseria meningitidis serogroup A outer Membrane vesicle as vaccine candidates
AR123545A1 (es) Composiciones de vacunas multivalentes y usos de las mismas
BR112022004921A2 (pt) Composições para neisseria meningitidis e métodos das mesmas
YÜKSEL MAYDA et al. History of Epidemics and COVID-19
JP2013516396A (ja) ロドコッカス・エクイに対する動物保護用組成物のための投与経路
WO2020084295A2 (en) Gut bacteria derived microvesicles for vaccine delivery
BR112023002872A2 (pt) Composição de vacina que induz uma resposta imune contra o vírus sars-cov-2, procedimento para obter as omvs, e, uso da composição de vacina
Senthilkumar et al. Gateways of pathogenic bacterial entry into host cells—salmonella
NZ739963B2 (en) Methods and compositions for immune protection against extra-intestinal pathogenic e. coli
CU23377A1 (es) Metodo para la incorporacion de antigenos en vesiculas de membrana externa de bacterias y formulaciones resultantes
Popoola et al. Pattern of bone metastasis in breast cancer patients at a radiotherapy facility in Lagos